louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05273008: Adductor Strength in Roller Hockey Athletes
Official title: Risk Factors for the Development of Groin Pain in Roller Hockey Athletes
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Groin Pain
Keywords: Roller hockey
Groin Pain
Risk factors
Lead sponsor: University of Oviedo
Sponsor class: OTHER
First posted: 2022-03-10
Enrollment: 251
Sex: MALE
Minimum age (years): 16
Maximum age (years): 35
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Athletes playing in the spanish roller hockey´s third division

Brief summary: Roller hockey athletes will be recruited along the season and will be examined for adductor strength and other potential groin pain risk factors.

Detailed description: Roller hockey athletes will be recruited and assess through the season. The assessment consist of an adductor, abductor strength measurement, Hip and Groin Outcome Score (HAGOS) completion and will be screened for other risk factors which are believed to cause groin pain (Age, previous injury)

Eligibility criteria: Inclusion Criteria:

* Participate in the roller hockey bronze division from spain

Exclusion Criteria:

* Deny participation

Primary outcomes:
measure: Adductor Strength
timeFrame: November 2021-March 2022
measure: Abductor strength
timeFrame: November 2021-March 2022
measure: Adductor to abductor ratio
timeFrame: November 2021-March 2022
Secondary outcomes:
measure: Hip and Groin Outcome Score
timeFrame: November 2021-March 2022
measure: 5 seconds squeeze test
timeFrame: November 2021-March 2022
Other outcomes:
Locations:
city: Oviedo
country: Spain
facility: Universidad de Oviedo
state: Asturias
Study officials:
affiliation: Universidad de Oviedo
name: Hugo Olmedillas, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02996708: Assessment of the Benefit of Teleconsultations for Children With Autism Spectrum Disorders
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Autism Spectrum Disorder
Child Autism
Keywords: Telemedicine
Health economics
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
First posted: 2016-12-19
Enrollment: 102
Sex: ALL
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Residents of medico-social structure accepting children and adolescent with autism disorders

Brief summary: The purpose of this study is to determine whether Teleconsultation would a)be effective and cost-effective by increasing the proportion of patients with Autism Spectrum Disorders having a correct follow-up, and less transportation, and b) get a high satisfaction from the parents and from the professionals


Eligibility criteria: Inclusion Criteria:

* All residents of medico-social structures accepting children and adolescent with autism disorders

Exclusion Criteria:

* Refusal of parents that their child use telemedicine
* Refusal of parents that their child participate to the research

Primary outcomes:
measure: Composite score: CARS, VABS evaluated once a year and ADI-R at least once in the lifetime
timeFrame: One year after the start of the "before" period and one year after the start of the "after" period
Secondary outcomes:
Other outcomes:
Locations:
city: Carrieres sur Poissy
country: France
facility: IME notre Ecole
city: Chambourcy
country: France
facility: Association Agir et Vivre l'Autisme
city: Collegien
country: France
facility: IME Eclair
city: Dammarie les Lys
country: France
facility: Association UNI-TEDS
city: Paris
country: France
facility: Hôpital Sainte Anne
city: Vert saint denis
country: France
facility: IME Le Reverdi
Study officials:
affiliation: Hôpital Sainte Anne
name: Catherine Doyen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03232008: Canderel:Effects on Blood Glucose Concentration and Appetite Scores
Official title: The Effects of Canderel (Aspartame and Acesulfame-k Blend) on Blood Glucose Concentration and Appetite Scores in Humans: a Randomised Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Appetitive Behavior
Glucose Metabolism Disorders
Keywords: Blood glucose
Appetite
Lead sponsor: King's College London
Sponsor class: OTHER
First posted: 2017-07-27
Enrollment: 110
Sex: ALL
Minimum age (years): 18
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: This study investigates the effects of Canderel, an aspartame and acesulfame-k blend artificial sweetener powder, on post-postprandial blood glucose levels and appetite scores.

Detailed description: The study is separated into two parts: A) investigating the effects of artificial sweeteners in combination with complex carbohydrates; and B) investigating the effects of artificial sweeteners in combination with simple sugars.

A) Participants will be randomly given either the placebo drink (3g of maltodextrin dissolved in 250ml of water) or the Canderel drink (3g of Canderel dissolved in 250ml of water) alongside an isocaloric high carbohydrate breakfast. Blood glucose measurements will be obtained through finger pricking and appetite will be measured using self-reported visual analog scores rating hunger, desire to eat, fullness and alertness for up to 3 hours after breakfast.

B)Participants will be randomly given either the placebo drink (3g of Lyle's Golden syrup and 3g of maltodextrin dissolved in 250ml of water) or the Canderel+sugars drink (3g of Canderel and 3g of Lyle's Golden syrup dissolved in 250ml of water) . Blood glucose measurements will be obtained through finger pricking and appetite will be measured using self-reported visual analog scores rating hunger, desire to eat, fullness and alertness for up to 3 hours after drink

Eligibility criteria: Inclusion Criteria:

* Healthy male and female adults (18-64)

Exclusion Criteria:

-

Primary outcomes:
measure: Change in Blood glucose
timeFrame: 0-180min (Measured from baseline to 90min every 15min; 90-180min every 30min)
measure: Change in Appetite
timeFrame: 0-180min (Measured from baseline to 90min every 15min; 90-180min every 30min)
Secondary outcomes:
Other outcomes:
Locations:
city: London
country: United Kingdom
facility: King's College London
Study officials:
affiliation: King's College London
name: Dr. Christopher Corpe
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05997108: Platelet and Red Blood Cell Volume Indices as Inflammatory Biomarkers in Ankylosing Spondylitis
Official title: Platelet and Red Blood Cell Volume Indices as Inflammatory Biomarkers in Ankylosing Spodylitis
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Ankylosing Spondylitis
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2023-08-18
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: PATIENT WITH DISEASE DURATION OF MORE THAN 6 MONTHS

-AGE MORE THAN 18 YEARS

Brief summary: this study aims to determine the relatioships among the NLR ,PLR ,MLR ,red cell volume and platelet volume indices levels as biomarkers in ankylosing spondylitis.


Eligibility criteria: Inclusion Criteria:

* PATIENT WITH DISEASE DURATION OF MORE THAN 6 MONTHS
* AGE MORE THAN 18 YEARS

Exclusion Criteria:

* PATIENT WITH CARDIAC ,CEREBROVASCULAR AND HEMATOLOGIC DIEASE
* PTIENT WITH HYPERTENSION ,DIABETES ,METABOLIS SYNDROMES AND OTHER AUTOIMMUNE RHEUMATIC DISEASES.

Primary outcomes:
measure: platelet
timeFrame: 6 months
measure: Red blood cell
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Sohag
country: Egypt
facility: Sohag university Hospital
Study officials:
References:
citation: Azab B, Torbey E, Singh J, Akerman M, Khoueiry G, McGinn JT, Widmann WD, Lafferty J. Mean platelet volume/platelet count ratio as a predictor of long-term mortality after non-ST-elevation myocardial infarction. Platelets. 2011;22(8):557-66. doi: 10.3109/09537104.2011.584086. Epub 2011 Jun 30.
citation: Coutant F, Miossec P. Evolving concepts of the pathogenesis of rheumatoid arthritis with focus on the early and late stages. Curr Opin Rheumatol. 2020 Jan;32(1):57-63. doi: 10.1097/BOR.0000000000000664.
citation: Bekdas M, Goksugur SB, Sarac EG, Erkocoglu M, Demircioglu F. Neutrophil/lymphocyte and C-reactive protein/mean platelet volume ratios in differentiating between viral and bacterial pneumonias and diagnosing early complications in children. Saudi Med J. 2014 May;35(5):442-7.
citation: Kumano Y, Hasegawa Y, Kawahara T, Yasui M, Miyoshi Y, Matsubara N, Uemura H. Pretreatment Neutrophil to Lymphocyte Ratio (NLR) Predicts Prognosis for Castration Resistant Prostate Cancer Patients Underwent Enzalutamide. Biomed Res Int. 2019 Jan 20;2019:9450838. doi: 10.1155/2019/9450838. eCollection 2019.
Clinical trial NCT06758908: Prevelance, Predictors and Outcome of Sepsis Associated Liver Injury (SALI)
Official title: Prevelance, Predictors and Outcome of Sepsis Associated Liver Injury (SALI)
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Liver Injuries
Lead sponsor: Assiut University
Sponsor class: OTHER
Collaborators: name: Investigator
First posted: 2025-01-06
Enrollment: 100
Sex: ALL
Minimum age (years): 15
Maximum age (years): 75
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: all people between 15 to 75 years

Brief summary: prevelance, predictors and outcome of sepsis associated liver injury (SALI)

Detailed description: patient with liver disease and sepsis at the same time

Eligibility criteria: Inclusion Criteria:

* clinical diagnosis of SALI
* must take liver support

Exclusion Criteria:

* SALI
* Thyroid disease

Primary outcomes:
measure: prevelance, predictors and outcome of sepsis associated liver injury (SALI)
timeFrame: baseline
measure: 28 days mortality
timeFrame: baseline
measure: patient shouldn't be in pain
timeFrame: baseline
Secondary outcomes:
measure: patient stay in hospital 2weeks
timeFrame: baseline
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01152008: Use of Laser Speckle to Study Cutaneous Blood Flow at Exercise in Healthy Subjects
Official title: Evaluation Chez Des Sujets Sains d'Une Nouvelle Technique d'étude de la Microcirculation cutanée
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Microcirculation
Keywords: Microcirculation
laser flowmetry
Skin
Physiology
Lead sponsor: University Hospital, Angers
Sponsor class: OTHER_GOV
First posted: 2010-06-29
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: healthy volunteers

Brief summary: We aim to test the hypothesis that Laser speckle contrast imaging allows for the measurement of cutaneous blood flow during exercise.

Detailed description: Ischemia and post occlusive reactive hyperhemia in the skin is tested in healthy normal subjects at rest and during cycle exercise.

Eligibility criteria: Inclusion Criteria:

* Healthy volunteers
* Affiliation to the French health system

Exclusion Criteria:

* Any disease or chronic treatment

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Angers
country: France
facility: University Hospital
Study officials:
affiliation: University Hospital in Angers
name: Guillaume MAHE, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Mahe G, Haj-Yassin F, Rousseau P, Humeau A, Durand S, Leftheriotis G, Abraham P. Distance between laser head and skin does not influence skin blood flow values recorded by laser speckle imaging. Microvasc Res. 2011 Nov;82(3):439-42. doi: 10.1016/j.mvr.2011.06.014. Epub 2011 Jul 14.
Clinical trial NCT02150408: Evaluation of PET-CT Using Somatostatin Agonists Labeled With Gallium68 in Neuroendocrine Tumors
Official title: Evaluation of PET-CT Using Somatostatin Agonists Labeled With Gallium68 in Neuroendocrine Tumors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Gastro-Entero-Pancreatic Tumors (GEPs)
Lead sponsor: Assistance Publique Hopitaux De Marseille
Sponsor class: OTHER
First posted: 2014-05-29
Enrollment: 35
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Gastro-Entero-Pancreatic tumors (GEPs) are a subset of Neuroendocrine tumors (NETs) derived from the primitive gut and include digestive and bronchial NETs.

Historically, the gold standard in their functional exploration is the "conventional" somatostatin receptors scintigraphy (SRS) labeled with Indium-111 (Octreoscan®). This reference imaging is complementary to Tomography (CT) and liver MRI. However SRS sensitivity is moderate (60 %), because of its intrinsic detection limits, which could delay the diagnosis or lead to inappropriate therapy.

The use of somatostatin agonists (DOTATOC, DOTATATE, DOTANOC), radiolabeled with gallium-68 (68Ga) enables targeting of Somatostatin receptors (SSTRs) with a PET resolution. This has improved diagnosis of TNE with a gain in sensitivity of over 20% compared to SRS. Furthermore, patient irradiation and imaging protocol are significantly reduced.


Eligibility criteria: Inclusion Criteria:

* • Age ≥ 18,

  * Patient with one of the following situations : suspicion of GEP, initial staging of non-metastatic GEP, GEP with unknown primary tumor, Restaging of GEP justifying focused therapeutic approach
  * Reference imaging within the last 3 months: multiphasic thoracoabdominal CT scan, liver MRI and SRS (SPECT/CT).

Exclusion Criteria:

* Pregnant or breast-feeding woman
* Other cancer disease
* GEP with grade 3 tumours
* Non GEP TNE (paragangliome, medullar thyroid cancer)

Primary outcomes:
measure: interest of the realization of 68Ga-DOTATATE PET-CT in the detection of tumor sites in TNE diagnosis, staging and restaging
timeFrame: 12-15 months
Secondary outcomes:
measure: therapeutic impact of 68Ga-DOTATATE PET-CT in addition to reference imaging (SRS, CT, MRI): we will document the rate of changes in treatment options induced by PET-CT
timeFrame: 12-15 months
Other outcomes:
measure: therapeutic impact of 68Ga-DOTATATE PET-CT in addition to reference imaging (SRS, CT, MRI): we will document the rate of changes in treatment options induced by PET-CT
timeFrame: 12-15 months
Locations:
city: Marseille
country: France
facility: Assistance Publique Hopitaux de Marseille
Study officials:
affiliation: Assistance Publique Hopitaux De Marseille
name: David TAIEB, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01191008: Long Term Use Of Xalacom In Patients Glaucoma Or Ocular Hypertension
Official title: Special Investigation Of Long Term Use Of Xalacom(Regulatory Post Marketing Commitment Plan)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Glaucoma
Ocular Hypertension
Keywords: Xalacom Regulatory post marketing commitment plan safety
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2010-08-30
Enrollment: 661
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: The patients whom an investigator involving A6641056 prescribes the Xalacom® Combination Eye Drops.

Brief summary: The objective of this Investigation is to evaluate the safety and efficacy of long-term treatment with Xalacom in medical practice. Also, occurrence of unknown and known adverse drug reactions (ADRs) in subjects treated with Xalacom will be monitored during the survey period, and whether an additional treatment outcome investigation and/or a post-marketing clinical study is required in the future will be determined.

Detailed description: All the patients whom an investigator prescribes the first Xalacom® should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.

Eligibility criteria: Inclusion Criteria:

* Patients need to be administered Xalacom® in order to be enrolled in the surveillance.

Exclusion Criteria:

* Patients not administered Xalacom®.

Primary outcomes:
measure: Number of Participants WithTreatment-Related Adverse Events
timeFrame: Max 104 weeks
measure: Clinical Effectiveness Rate
timeFrame: Max 104 weeks
Secondary outcomes:
Other outcomes:
measure: Number of Participants With Treatment-Related Adverse Events Unexpected From Japanese Package Insert
timeFrame: Max 104 weeks
Locations:
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT02461108: Nudging Nutrition With Monetary Incentives Environmental Cues
Official title: Nudging Nutrition: Evaluating the Impact of Monetary Incentives and Environmental Cues on Food Choices
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obesity
Food Labeling
Health Behavior
Diet
Keywords: Public policy
Food choice
Nutrition labeling
Fat tax
Vegetable subsidy
Behavioral economics
Health behavior
Lead sponsor: Cornell University
Sponsor class: OTHER
Collaborators: name: National Institutes of Health (NIH)
name: Ohio State University
name: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
First posted: 2015-06-03
Enrollment: 221
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: FACTORIAL

Brief summary: The investigators hypothesize that monetary incentives and messaging, such as making nutritious foods relatively less expensive than less nutritious foods and framing the price difference in a positive or negative way, will influence purchasing behavior of households.

Detailed description: In this study, 239 loyalty card shoppers were recruited at Hannaford grocery stores to participate in a study in which a 10% price difference between nutritious and less nutritious foods was introduced. and then framed as a subsidy, tax, or a combination of a tax and subsidy. To determine whether or not the framing of the price difference influenced purchasing behavior, the difference was framed as a subsidy on nutritious foods, a tax on less nutritious foods, and a combination of a tax and subsidy on less nutritious and nutritious foods, respectively. The purpose of this study was to examine the general impact of this price difference on purchases of nutritious and less nutritious foods, and whether or not the framing of the price difference had a differential effect on behavior.

Eligibility criteria: Inclusion Criteria:

* Loyalty card shoppers at Hannaford grocery stores

Exclusion Criteria:

* No children in household
* Less than 75% of food purchases made at Hannaford grocery stores

Primary outcomes:
measure: Change in expenditures on nutritious and less nutritious foods
timeFrame: 8 months
Secondary outcomes:
measure: Change in quantities purchased of nutritious and less nutritious foods
timeFrame: 8 months
measure: Change in expenditures on nutritious and less nutritious foods in specific food categories.
timeFrame: 8 months
Other outcomes:
Locations:
city: New York City
country: United States
facility: New York City School District
state: New York
Study officials:
affiliation: Cornell University
name: Brian Wansink, PhD
role: STUDY_DIRECTOR
affiliation: Cornell University
name: David Just, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Pope L, Hanks AS, Just DR, Wansink B. New Year's res-illusions: food shopping in the new year competes with healthy intentions. PLoS One. 2014 Dec 16;9(12):e110561. doi: 10.1371/journal.pone.0110561. eCollection 2014.
Clinical trial NCT04903808: Clinical And Cost- Effectiveness of Allium Sativum Oil (Garlic Oil ) Versus Mineral Trioxide Aggregate in Primary Molars Pulpotomy in Group of Egyptian Children : A Randomised Clinical Pilot Study.
Official title: Clinical And Cost- Effectiveness of Allium Sativum Oil Versus Mineral Trioxide Aggregate in Primary Molars Pulpotomy in Group of Egyptian Children : A Randomised Clinical Pilot Study.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
PHASE3
Conditions: Carious Primary Molars
Keywords: Allium sativum oil
MTA
pulpotomy
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2021-05-27
Enrollment: 26
Sex: ALL
Minimum age (years): 5
Maximum age (years): 7
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: It is a double-blinded randomised clinical trial with equal randomisation parallel design with allocation ratio 1:1
Primary purpose: TREATMENT

Brief summary: Allium Sativum oil is advocated to prove the capability of new natural products in replacing higher cost pharmacological materials, while achieving the same successful clinical and radiographic long-term results.

Detailed description: One of the most challenging subjects in paediatric dentistry is choosing the ideal pulp medication material that has the required properties such as preserving the vitality of the remaining intact pulp and stimulating its repair. This material should prevent pathological root resorption.Clinical and cost effectiveness trials from different countries are useful to determine which medicament should be advocated in which economic setting . Alternative pulpotomy materials clinically effective as MTA but with lower cost should be studied .

Eligibility criteria: Inclusion Criteria:

* Apparently healthy children aged from 5- 7 years.
* Children not having antibiotics in the past 14 days.
* Cooperative children.
* Children are having at least two carious asymptomatic second primary molars.

Exclusion Criteria:

* Uncooperative children.
* Immunocompromised children.
* Children with clinical or radiographic symptoms

Primary outcomes:
measure: Clinical effectiveness
timeFrame: 1 year follow up
Secondary outcomes:
measure: Cost-effectiveness
timeFrame: 1 year follow up
Other outcomes:
Locations:
Study officials:
References: